Cadrenal’s CAD-1005 Phase 2 Data Earns Late-Breaking Spot at ISTH 2026 — Cadrenal Therapeutics, Inc.

Event summary

Cadrenal Therapeutics' CAD-1005 Phase 2 study data selected for late-breaking oral presentation at ISTH 2026 Congress in Paris.
First-ever randomized, blinded, placebo-controlled trial in Heparin-Induced Thrombocytopenia (HIT).
CAD-1005 targets 12-lipoxygenase, a novel approach to address immune-mediated platelet activation in HIT.
Phase 3-ready with peak $2 billion annual revenue potential in the HIT market.

The big picture

Cadrenal’s selection for ISTH underscores the clinical and commercial potential of CAD-1005, a first-in-class therapy addressing a critical gap in HIT treatment. The $2 billion market opportunity highlights the strategic importance of this novel approach in immune-mediated thrombotic disorders. Success here could redefine acute thrombotic care and validate 12-lipoxygenase inhibition as a key therapeutic pathway.

What we're watching

Clinical Validation: Whether the Phase 2 data will confirm CAD-1005's potential to shift the HIT treatment paradigm.
Regulatory Pathway: The pace at which Cadrenal advances to Phase 3 and secures approvals for CAD-1005.
Market Penetration: How Cadrenal positions CAD-1005 in a HIT market with significant unmet needs and no approved targeted therapies.